Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis

Haruhisa Kitano, Joon Yong Chung, Kyung Hee Noh, Young Ho Lee, Tae Woo Kim, Seok Hyung Lee, Soo Heang Eo, Hyung Jun Cho, Chel Hun Choi, Shuhei Inoue, Jun Hanaoka, Junya Fukuoka, Stephen M. Hewitt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC). Methods: The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis. Results: Positive correlations between SCP3 and VEGF-C expression (R2 = 0.743) and VEGF-D expression (R2 = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0%), 22 (24.7%), 27 (30.3%), 27 (30.3%), and 24 cases (27.0%), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008). Conclusions: SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy.

Original languageEnglish
Article number138
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Synaptonemal Complex
Lymphangiogenesis
Vascular Endothelial Growth Factor D
Vascular Endothelial Growth Factor C
Non-Small Cell Lung Carcinoma
Lymph Nodes
Cells
Neoplasm Metastasis
Vascular Endothelial Growth Factor B
Proteins
Vascular Endothelial Growth Factor A
Lung Neoplasms
Cell Line
Image analysis
Tumors
Neoplasms
Hazards
Multivariate Analysis
Immunohistochemistry

Keywords

  • Lymph node metastasis
  • Lymphangiogenesis
  • Non-small cell lung cancer
  • SCP3
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis. / Kitano, Haruhisa; Chung, Joon Yong; Noh, Kyung Hee; Lee, Young Ho; Kim, Tae Woo; Lee, Seok Hyung; Eo, Soo Heang; Cho, Hyung Jun; Choi, Chel Hun; Inoue, Shuhei; Hanaoka, Jun; Fukuoka, Junya; Hewitt, Stephen M.

In: Journal of Translational Medicine, Vol. 15, No. 1, 138, 2017.

Research output: Contribution to journalArticle

Kitano, H, Chung, JY, Noh, KH, Lee, YH, Kim, TW, Lee, SH, Eo, SH, Cho, HJ, Choi, CH, Inoue, S, Hanaoka, J, Fukuoka, J & Hewitt, SM 2017, 'Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis', Journal of Translational Medicine, vol. 15, no. 1, 138. https://doi.org/10.1186/s12967-017-1241-5
Kitano, Haruhisa ; Chung, Joon Yong ; Noh, Kyung Hee ; Lee, Young Ho ; Kim, Tae Woo ; Lee, Seok Hyung ; Eo, Soo Heang ; Cho, Hyung Jun ; Choi, Chel Hun ; Inoue, Shuhei ; Hanaoka, Jun ; Fukuoka, Junya ; Hewitt, Stephen M. / Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.
@article{f36c516ae37b436988aa4410859a5a06,
title = "Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis",
abstract = "Background: The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC). Methods: The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis. Results: Positive correlations between SCP3 and VEGF-C expression (R2 = 0.743) and VEGF-D expression (R2 = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0{\%}), 22 (24.7{\%}), 27 (30.3{\%}), 27 (30.3{\%}), and 24 cases (27.0{\%}), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008). Conclusions: SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy.",
keywords = "Lymph node metastasis, Lymphangiogenesis, Non-small cell lung cancer, SCP3, Vascular endothelial growth factor",
author = "Haruhisa Kitano and Chung, {Joon Yong} and Noh, {Kyung Hee} and Lee, {Young Ho} and Kim, {Tae Woo} and Lee, {Seok Hyung} and Eo, {Soo Heang} and Cho, {Hyung Jun} and Choi, {Chel Hun} and Shuhei Inoue and Jun Hanaoka and Junya Fukuoka and Hewitt, {Stephen M.}",
year = "2017",
doi = "10.1186/s12967-017-1241-5",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis

AU - Kitano, Haruhisa

AU - Chung, Joon Yong

AU - Noh, Kyung Hee

AU - Lee, Young Ho

AU - Kim, Tae Woo

AU - Lee, Seok Hyung

AU - Eo, Soo Heang

AU - Cho, Hyung Jun

AU - Choi, Chel Hun

AU - Inoue, Shuhei

AU - Hanaoka, Jun

AU - Fukuoka, Junya

AU - Hewitt, Stephen M.

PY - 2017

Y1 - 2017

N2 - Background: The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC). Methods: The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis. Results: Positive correlations between SCP3 and VEGF-C expression (R2 = 0.743) and VEGF-D expression (R2 = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0%), 22 (24.7%), 27 (30.3%), 27 (30.3%), and 24 cases (27.0%), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008). Conclusions: SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy.

AB - Background: The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC). Methods: The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis. Results: Positive correlations between SCP3 and VEGF-C expression (R2 = 0.743) and VEGF-D expression (R2 = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0%), 22 (24.7%), 27 (30.3%), 27 (30.3%), and 24 cases (27.0%), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008). Conclusions: SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy.

KW - Lymph node metastasis

KW - Lymphangiogenesis

KW - Non-small cell lung cancer

KW - SCP3

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85027587245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027587245&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1241-5

DO - 10.1186/s12967-017-1241-5

M3 - Article

C2 - 28623914

AN - SCOPUS:85027587245

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 138

ER -